7th Sep 2026 01:08
AstraZeneca PLC - Cambridge, England-based pharmaceuticals firm - Welcomes the US Food & Drug Administration's accelerated approval of Etcamah for use alongside a cyclin‑dependent kinase 4 and 6 inhibitor, a type of medicine that slows cancer cell growth, in adults with advanced hormone‑driven breast cancer. Says Etcamah, which blocks the effect of estrogen on tumour cells, is cleared for patients who develop a mutation in the estrogen receptor 1 gene, a change that can make standard hormone treatment stop working. AstraZeneca says the decision is supported by Serena-6 phase three trial showing the combination keeps the disease from worsening for longer than current first‑line therapy. The firm adds that safety findings are in line with what is already known about the medicines used. Etcamah is also approved in more than 30 countries.
"The Etcamah combination reflects AstraZeneca's leadership in redefining breast cancer care by pioneering a new approach using circulating tumour [deoxyribonucleic acid] and is the first and only medicine of its type in the 1st-line setting," says Dave Fredrickson, executive vice president, Oncology Haematology Business Unit.
Current stock price: GBP12,146.00
12-month change: up 1.5%
By Judy Amaca, Alliance News reporter Asia-Pacific
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca